Not necessarily as Gleevec was tested on top of at least 2 medications as an add-on therapy in patients with more advanced disease:
Criteria Inclusion Criteria:
Current diagnosis of pulmonary arterial hypertension according to the Dana Point 2008 meeting PVR = 800 dynes.sec.cm-5 despite treatment with 2 or more specific PAH therapies: endothelial receptor antagonists, phosphodiesterase 5 inhibitors, and prostacyclin analogues WHO functional class II - IV 6 MWD = 150 meters and = 450 meters at screening
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.